Gregory Stea
Keine laufenden Positionen mehr
Profil
Gregory Stea served as Vice President-Sales at Amgen, Inc. from 1988 to 1997.
He then worked as Principal at Glaxo Pharmaceuticals, Inc. from 1982 to 1988.
Later, he served as Senior Vice President-Commercial Operations at Cubist Pharmaceuticals LLC from 2002 to 2015.
From 2015 to 2019, he worked as Independent Director at Achaogen, Inc. Mr. Stea completed his undergraduate degree from Temple University (Pennsylvania).
Ehemalige bekannte Positionen von Gregory Stea
| Unternehmen | Position | Ende |
|---|---|---|
| ACHAOGEN | Direktor/Vorstandsmitglied | 23.07.2019 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01.02.2015 |
| AMGEN INC. | Vertrieb & Marketing | 01.01.1997 |
| Glaxo Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Ausbildung von Gregory Stea
| Temple University (Pennsylvania) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
| Glaxo Pharmaceuticals, Inc. |
